Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.39 |
| ▸ | HTR7 | P34969 | 9/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626923 | 0.90 | HTR1A (0.40) | HTR1AHTR7POLBDRD2HTR6 | |
| SCHEMBL627436 | 0.86 | HTR1A (0.47) | HTR1AHTR7SLC6A9SMN1; SMN2ALDH1A1 | |
| SCHEMBL627240 | 0.85 | SLC6A9 (0.42) | HTR1AHTR7POLBDRD2HTR6 | |
| SCHEMBL867941 | 0.85 | LMNA (0.46) | SLC6A9ALDH1A1LMNA | |
| SCHEMBL10269480 | 0.82 | POLB (0.36) | POLBSLC6A9SMN1; SMN2USP9XNPSR1 | |
| SCHEMBL627155 | 0.80 | SLC6A9 (0.49) | HTR1AHTR7DRD2HTR6SLC6A9 | |
| SCHEMBL623281 | 0.79 | ALDH1A1 (0.38) | HTR1AHTR7POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL626869 | 0.78 | HTR1A (0.43) | HTR1AHTR7HTR6SLC6A9HTR2A | |
| SCHEMBL627013 | 0.76 | HTR1A (0.48) | HTR1AHTR7SLC6A9SMN1; SMN2ALDH1A1 | |
| SCHEMBL12473901 | 0.74 | ALDH1A1 (0.40) | POLBDRD2SMN1; SMN2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | claimed |
| US-9238619-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-9238619-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-19 | — | — | US | disclosed |
| US-8877794-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877794-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012020130-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | HTR1A 555/4885HTR7 374/4885POLB 3073/4885 |
| US-20120077796-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | HTR1A 555/4885HTR7 374/4885POLB 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.